// App-Quantinova.ai

: Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma

Researchers

Presenter

  • Ingmar Bruns

Principal Investigators

  • Mary Fitzgerald

  • George Mensing

  • Mei Tsung

  • Katerina Pardali

  • Philip Gardiner

  • David Keeling

  • Lena Axelsson

  • Marita Olsson

  • Cyrus Ghobadi

  • Oscar Walsh

  • Kristi Mclendon

  • Nicholas Farinola

  • Lara Hatchuel

  • David Close

Medical Centers

  • Pieris Pharmaceuticals, Boston, United States of America

  • Early Respiratory, Inflammation and Autoimmunity, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

  • Clinical Development, Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA), R & D BioPharmaceuticals, AstraZeneca, Gothenburg, Sweden

  • Nucleus Network, Melbourne, Australia

  • Q-Pharm PTY Limited, Herston, Australia

  • CMAX Clinical Research Pty Ltd, Adelaide, Australia

  • Haematology,Linear Clinical Research,Nedlands,Australia

  • Respiratory, Inflammation and Autoimmunity, Early Clinical Development, AstraZeneca, Gotherburg, Sweden

Locations

  • United States

  • Sweden

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Signal Transducer And Activator Of Transcription 6

Drug/Treatment

  • Nitric oxide

  • PRS060

  • IL-4

Outcome

  • N/A

Study Design

  • Placebo Control

  • Pharmacokinetics

  • Multiple Ascending Dose

Phase

  • NA

Study Id's

  • NCT03574805

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved